Neratinib

In response to the clinical pain point of postoperative recurrence risk of HER2-positive breast cancer, neratinib, as a small molecule tyrosine kinase inhibitor, irreversibly binds to the intracellular kinase domains of HER1, HER2 and HER4, blocks the conduction of downstream signaling pathways, and reduces the proliferation activity of tumor cells. It is mainly clinically used for extended adjuvant therapy of patients with HER2-positive early breast cancer who have completed adjuvant therapy with trastuzumab, and is the world's first oral targeted drug approved for this indication. Meanwhile, it can be combined with capecitabine for patients with advanced HER2-positive breast cancer who have received two or more anti-HER2 regimens, providing an important treatment option for prolonging the progression-free survival of patients and reducing the long-term recurrence risk.

The global neratinib market size was approximately USD 370 million in 2022, and the compound annual growth rate from 2023 to 2029 is expected to remain at around 8%. The growth drivers mainly come from the increased penetration rate of extended adjuvant therapy for early breast cancer and the expansion of indications in emerging markets. The Chinese market is currently in a rapid introduction period. In 2023, the sales volume in sample hospitals increased by more than 45% year-on-year, the competitive landscape is relatively concentrated, and the original research product still occupies a dominant position. Three domestic enterprises have been approved for generic preparations. With its inclusion in the National Medical Insurance Catalog in 2024, the market penetration rate is expected to further increase.

The original research enterprise of neratinib is Puma Biotechnology of the United States, with the trade name Nerlynx. The expiration date of its core compound patent in the United States is 2030, and the Chinese compound patent will expire in 2028. At present, the main dosage form approved by the original research is tablet, with the specification including 40 mg per tablet. The original research product has been included in the FDA Reference Listed Drug Catalog, and is also included in the *Catalog of Reference Preparations for Chemical Drugs* of China. In terms of domestic API registration, 5 enterprises have obtained CDE registration numbers for neratinib APIs, among which 3 are in A status, and 3 domestic enterprises have obtained approval for marketing of neratinib oral preparations. (Data as of March 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for neratinib API, covering the full spectrum of categories such as synthetic process intermediates, degradation impurities and enantiomers. Most products can be supplied from stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide stable material basis support for pharmaceutical enterprises in API R&D, quality research and consistency evaluation work.